文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

基于以色列2009-2024年全国监测数据预判PCV20或PCV21用于老年人免疫规划的侵袭性肺炎球菌疾病影响

Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024.
PubMed 文献 · Euro Surveill · 2026-01-01

该研究基于以色列2009-2024年全国主动监测数据,分析≥65岁成人侵袭性肺炎球菌疾病(IPD)血清型动态,评估PCV20或PCV21纳入成人国家免疫规划的潜在影响。共记录3553例IPD,2022-2024年PCV21独有血清型占25.5%,PCV20独有血清型占10.9%,PCV21覆盖更广但血清型谱仅部分重叠。

要点

  • 2022-2024年≥65岁成人中PCV21独有血清型IPD占25.5%,PCV20独有占10.9%。
  • PCV20独有血清型中14型 late/post-pandemic 发病率最高,为1.76/10万。
  • PCV21当前血清型覆盖更广,但两种疫苗血清型谱仅部分重叠。

核心结论

  • 在以色列≥65岁成人中,PCV21疫苗目前显示的血清型覆盖范围比PCV20更广。
  • PCV20与PCV21的血清型谱仅部分重叠,实施后血清型动态可能进一步变化,难以准确预测影响。

研究设计与样本

  • 全国主动IPD监测研究,2009-2024年,纳入≥65岁成人,按年龄组、单个血清型和疫苗血清型组评估每10万人口IPD发病率。
  • 共记录3553例IPD发作。

主要发现

  • 2014/15至2023/24期间除COVID-19时期外,全IPD发病率相对稳定。
  • late PCV13期(2014-2019,1210例)和late/post COVID-19大流行期(2021-2024,608例),PCV21独有血清型(VT21-only)发病率持续高于PCV20独有血清型(VT20-only)。
  • 2022-2024年,VT21-only IPD占全部IPD病例的25.5%,VT20-only占10.9%。
  • VT20-only血清型中,14型在late/post-pandemic期发病率最高,为1.76/10万。

临床怎么用

  • 成人IPD疫苗接种政策选择可参考本地血清型分布数据,PCV21在当前以色列老年人群中覆盖更广。
  • 需考虑PCV20纳入儿童免疫规划后可能引起的血清型替代动态,以及新引入疫苗血清型的实际效力未知。

局限性

  • PCV20实施于儿童NIP后的进一步血清型特异性动态可能影响预测准确性。
  • 新引入疫苗血清型的实际效力未知,使实施后影响难以准确预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDPneumococcal conjugate vaccines (PCVs) have reduced vaccine-type (VT) invasive pneumococcal disease (IPD) in older adults through direct and indirect effects. However, non-vaccine-type serotypes have emerged. Since the recently licensed PCV20 and PCV21 vaccines differ in serotype composition, epidemiological data are essential to guide adult vaccination policy.AIMWe aimed to assess serotype-specific IPD dynamics in older adults in Israel and evaluate the potential impact of implementing either the PCV20 or PCV21 vaccine in the adult National Immunisation Programme (NIP).METHODSIn a national active IPD surveillance study in Israel, 2009-2024, on adults aged ≥ 65 years, IPD incidence per 100,000 population was assessed by age group, individual serotype and VT group.RESULTSWe recorded 3,553 IPD episodes. All-IPD incidence was relatively stable between 2014/15 and 2023/24, excluding the COVID-19 period. In the late PCV13 period (2014-2019, 1,210 IPD episodes) and late/post COVID-19 pandemic (2021-2024, 608 episodes) periods, incidence of serotypes unique to PCV21 (VT21-only) was consistently higher than that of those unique to PCV20 (VT20-only). During 2022-2024, VT21-only IPD constituted 25.5% of all-IPD cases compared with 10.9% for VT20-only. Of the VT20-only serotypes, serotype 14 showed the highest late/post-pandemic incidence (1.76 per 100,000).CONCLUSIONSThe PCV21 vaccine currently demonstrates broader serotype coverage than PCV20 among older adults in Israel. However, the spectrum of serotypes only partially overlap. Potential further serotype-specific dynamics following PCV20 implementation in the paediatric NIP and unknown actual effectiveness of newly introduced vaccine serotypes make it difficult to accurately predict impact following implementation.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Rieger R, Yahav D, Margalit I, et al. Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024. Euro Surveill. 2026. PMID: 42141887. doi:10.2807/1560-7917.ES.2026.31.15.2500589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。